|2.||Cardiac Arrhythmias (Arrythmia)
|4.||Cardiac Sudden Death (Sudden Cardiac Arrest)
|1.||Maron, Barry J: 39 articles (09/2015 - 01/2002)|
|2.||Ackerman, Michael J: 32 articles (12/2015 - 06/2002)|
|3.||Ommen, Steve R: 28 articles (08/2015 - 06/2002)|
|4.||McKenna, William J: 25 articles (12/2014 - 01/2002)|
|5.||Carrier, Lucie: 23 articles (01/2016 - 08/2004)|
|6.||Elliott, Perry M: 20 articles (06/2014 - 05/2002)|
|7.||Seidman, Christine E: 17 articles (11/2015 - 01/2002)|
|8.||Semsarian, Christopher: 17 articles (02/2015 - 05/2004)|
|9.||Olivotto, Iacopo: 16 articles (11/2015 - 09/2003)|
|10.||Seidman, J G: 16 articles (11/2015 - 10/2000)|
|1.||Verapamil (Calan)FDA LinkGeneric
09/01/1981 - "Verapamil is extremely effective in the treatment of patients with hypertrophic cardiomyopathy. "
01/01/1987 - "The beneficial effect of verapamil in hypertrophic cardiomyopathy is related to improved relaxation and diastolic filling rather than to changes in passive elastic chamber properties.(ABSTRACT TRUNCATED AT 250 WORDS)"
11/01/1983 - "The negative inotropic effects of intravenous verapamil are potentially beneficial in patients with hypertrophic cardiomyopathy by decreasing left ventricular contractile function and increasing left ventricular volume. "
07/01/1998 - "Prior studies have shown an improvement in adults with hypertrophic cardiomyopathy who were treated with verapamil. "
07/01/1998 - "We sought to evaluate the safety and efficacy of acute and chronic treatment with verapamil in infants with hypertrophic cardiomyopathy. "
06/01/2000 - "All patients with hypertrophic obstructive cardiomyopathy included in this multicenter study were either refractory or intolerant to drugs and typically had pressure gradients higher than 30 mm Hg. In 83 patients, mean age 53 (18 to 82) years who responded favorably to a temporary pacing test, a DDD pacemaker was implanted. "
06/15/2006 - "In conclusion, DDD pacing is effective in reducing the LVOT gradient and improving functional capacity in adult patients with hypertrophic cardiomyopathy. "
01/01/1996 - "DDD pacing has been advocated as an effective treatment for drug refractory obstructive hypertrophic cardiomyopathy. "
07/15/2011 - "A case of hypertrophic cardiomyopathy with mid-ventricular obstruction (MVO) -- dramatic long-term improvement with a DDD pacemaker as assessed by diastolic paradoxical jet flow velocity."
12/01/1994 - "We previously reported that 6 to 12 weeks of dual-chamber (DDD) pacing results in clinical and hemodynamic improvement in obstructive hypertrophic cardiomyopathy (HCM). "
|3.||Amiodarone (Amiodarona)FDA LinkGeneric
01/01/1992 - "Amiodarone is an antiarrhythmic drug with negative inotropic effect; therefore an study of hemodynamic effects of this drug in obstructive hypertrophic cardiomyopathy was performed. "
04/01/1998 - "Hypertrophic cardiomyopathy: is there a role for amiodarone?"
11/01/1994 - "Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: risk stratification and effect of low dose amiodarone."
09/01/1992 - "We conclude that in patients with hypertrophic cardiomyopathy, amiodarone prolongs QTc but reduces QTc dispersion. "
09/01/1992 - "To compare QT interlead variability (dispersion) in patients who receive a class III antiarrhythmic with those not on antiarrhythmic therapy, we measured QT in all 12 leads of a standard ECG in 24 patients with hypertrophic cardiomyopathy, 12 (50%) of whom were on amiodarone monotherapy and 12 (50%) who were not on amiodarone or other cardioactive medication which could affect QT. "
|4.||Disopyramide (Norpace)FDA LinkGeneric
04/19/2005 - "In this study we assessed the long-term efficacy and safety of disopyramide for patients with obstructive hypertrophic cardiomyopathy (HCM). "
09/01/1995 - "The purpose of this study was to estimate the effect of disopyramide on left ventricular diastolic function in patients with hypertrophic obstructive cardiomyopathy. "
05/01/1991 - "The present study clarified the effect of disopyramide on left-ventricular function in patients with hypertrophic cardiomyopathy (5 obstructive type: HOCM, 21 non-obstructive type: HNCM). "
12/01/2015 - "Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug."
05/01/2012 - "A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy."
|5.||Nifedipine (Adalat)FDA LinkGeneric
11/01/1983 - "The mechanism of action of nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy is unclear and could result from an improvement in myocardial inactivation or from systemic vasodilation and left ventricular unloading. "
10/02/1980 - "Improved diastolic function and systolic performance in hypertrophic cardiomyopathy after nifedipine."
02/01/1990 - "Effects of nifedipine on left ventricular diastolic function in patients with asymptomatic or minimally symptomatic hypertrophic cardiomyopathy."
04/01/1988 - "Relation between serum nifedipine concentration and hemodynamic effects in nonobstructive hypertrophic cardiomyopathy."
01/01/1988 - "Diastolic left ventricular function after nifedipine in healthy subjects and hypertrophic obstructive cardiomyopathy (CAPS) patients."
|6.||Diltiazem (Cardizem)FDA LinkGeneric
09/01/1991 - "The results indicate that diltiazem provides an effective and apparently safe treatment for the management of feline hypertrophic cardiomyopathy."
11/01/1984 - "Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: an echocardiographic study."
02/01/2015 - "The study sought to assess the safety, feasibility, and effect of diltiazem as disease-modifying therapy for at-risk hypertrophic cardiomyopathy (HCM) mutation carriers. "
02/01/2015 - "Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression."
02/01/2015 - "(Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem; NCT00319982)."
|7.||Propranolol (Inderal)FDA LinkGeneric
01/01/1980 - "Left ventricular filling was studied by echocardiography and cineangiography in 37 patients with hypertrophic cardiomyopathy with obstruction before and during long-term oral beta blockade (166 +/- 61 mg propranolol for 15.6 +/- 21 months on average) in order to determine the mechanism of symptomatic improvement in these patients. "
10/01/2002 - "The aim of this study was to investigate the influence of administration of beta-blocker propranolol on cyclic variation in patients with hypertrophic cardiomyopathy and persistent left ventricular (LV) pressure gradient and to test the hypothesis that the reduction of LV pressure gradient would be related to the change in regional contractile function. "
06/01/1985 - "Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study."
09/01/2005 - "In this case report, we present a 5-year follow-up of symmetrical concentric hypertrophic cardiomyopathy (HCM) in an FRDA patient treated with high-dose propranolol. "
10/01/2002 - "Influence of propranolol infusion on cyclic variation of myocardial integrated backscatter in hypertrophic obstructive cardiomyopathy."
03/01/1994 - "One can rationalize that the symptomatic elderly patient with isolated diastolic dysfunction can be treated effectively with calcium antagonists but, once again, there are no major trials evaluating any drug in the management of patients with isolated diastolic function not due to hypertrophic cardiomyopathy. "
11/01/1983 - "Recent hemodynamic studies have shown the importance of diastolic myocardial dysfunction in patients with hypertrophic cardiomyopathy, and demonstrated that calcium-blocking agents may enhance myocardial performance by reducing this dysfunction (Goodwin, 1982; Lorell et al., 1980, 1982; Sanderson et al., 1977). "
01/01/2006 - "Genes, calcium and modifying factors in hypertrophic cardiomyopathy."
01/01/2004 - "Rather, suppressed SR calcium uptake due to reduced SERCA2a expression and hypophosphorylation of PLB due to changes in protein phosphatase expression may play important roles in the diastolic dysfunction of Ras-mediated hypertrophic cardiomyopathy."
01/01/2004 - "Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart."
|9.||Ethanol (Ethyl Alcohol)IBA
04/01/2013 - "It is also helpful in evaluating the effect of transcoronary ethanol septal ablation and prognosis in patients with hypertrophic cardiomyopathy, which suggests that it is an important imaging method in the comprehensive evaluation of hypertrophic cardiomyopathy."
11/01/2002 - "Transcoronary ethanol septal ablation (TESA) is a novel treatment for obstructive hypertrophic cardiomyopathy (HOCM). "
12/01/2006 - "Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a single-center prospective, and randomized study."
03/01/2005 - "This prospective, randomized study evaluates the association between ethanol dose and postprocedural hemodynamic changes in 42 patients treated by alcohol septal ablation for obstructive hypertrophic cardiomyopathy. "
05/01/2008 - "After establishing that the majority of outflow obstruction was dynamic and related to the hypertrophic cardiomyopathy, the patient underwent successful ethanol septal ablation."
|10.||Dexamethasone (Maxidex)FDA LinkGeneric
06/01/1993 - "The hypertrophic obstructive cardiomyopathy appeared and progressed during dexamethasone therapy and resolved completely after its cessation. "
08/01/2015 - "Hypertrophic cardiomyopathy (HCM) is a transient side effect observed after multiple doses of dexamethasone. "
08/01/2015 - "Hypertrophic Cardiomyopathy After a Single Dose of Dexamethasone in a Preterm Infant."
03/01/2014 - "Hypertrophic cardiomyopathy is a frequently reported, although transient, side effect of high-dose dexamethasone administration. "
08/01/2011 - "These data are consistent with normal myocardial relaxation, suggesting that long-term diastolic function is reassuringly normal in children who received dexamethasone as premature infants with resolution of hypertrophic cardiomyopathy."
|1.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
01/01/2006 - "Safety and efficacy of implantable cardioverter defibrillator (ICD) have been demonstrated in high risk patients with hypertrophic cardiomyopathy in a large clinical study. "
11/01/2008 - "Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients."
04/09/2013 - "The aim of this study was to determine the efficacy of implantable cardioverter-defibrillators (ICDs) in children and adolescents with hypertrophic cardiomyopathy (HCM). "
04/01/2013 - "This study sought to determine factors predicting appropriate implantable cardioverter defibrillator (ICD) therapy in a large cohort of patients with hypertrophic cardiomyopathy (HCM). "
11/18/2008 - "The purpose of this study was to examine the effects of alcohol septal ablation (ASA) on ventricular arrhythmias among patients with obstructive hypertrophic cardiomyopathy (HCM), as measured by appropriate implantable cardioverter-defibrillator (ICD) discharges. "
|2.||Drug Therapy (Chemotherapy)
01/01/2005 - "Echocardiographic characteristics predicting efficacy of drug therapy in patients with hypertrophic obstructive cardiomyopathy."
01/01/2013 - "The aim of this non-randomized cohort study was to compare subjective and objective outcomes in hypertrophic cardiomyopathy patients undergoing drug therapy, surgical myotomy-myectomy, dual-chamber pacing and alcohol septal ablation. "
01/01/2005 - "Our results demonstrate that drug therapy effectively reduces the LVOT gradient in patients with asymmetric septal hypertrophy and a less severe LVOT gradient."
01/01/2005 - "Seven of eight patients with an asymmetric septal hypertrophy (ASH) ratio >==1.3 and LVOT gradient <100 mm Hg were responsive to drug therapy. "
05/01/1999 - "A 13-year-old boy with hypertrophic obstructive cardiomyopathy was treated with dual-chamber pacing after severe progression of left ventricular outflow tract obstruction and of clinical symptoms despite drug therapy. "
10/01/2014 - "Recent studies suggest that QTVI may help clinicians choosing the appropriate implantable cardiovester defibrillator timing implantation, in patients with dilated or hypertrophic cardiomyopathy or CHF because of its efficacy in patient evaluation and follow-up. "
01/01/1998 - "The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy."
01/20/2015 - "Implantation of a defibrillator in a pregnant woman with hypertrophic cardiomyopathy under echocardiographic guidance: a case report."
10/01/2013 - "Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study."
10/01/2011 - "We present a case of a symptomatic myocardial bridge in a 5-year-old boy with mild hypertrophic cardiomyopathy who underwent supra-arterial myotomy, automatic defibrillator placement, and long-term Beta-blocker therapy. "
|4.||Heart Transplantation (Grafting, Heart)
12/07/2013 - "Treatment of children with hypertrophic cardiomyopathy might be improved if the risk of death or heart transplantation could be predicted by risk factors present at the time of diagnosis. "
04/01/2013 - "The SE studies that remained unclassified by the 2011 AUC were related to the assessment of specialized cardiac conditions, including hypertrophic cardiomyopathy and follow-up after heart transplantation. "
07/01/1991 - "Although the number of patients is small and the study is preliminary, indium-111 antimyosin antibody imaging could be of value in establishing prognosis of patients with dilated and hypertrophic cardiomyopathy, in selecting patients for cardiac transplantation, and in evaluating the effects of therapeutic interventions."
03/01/2015 - "The father received a pacemaker and underwent heart transplantation because of hypertrophic cardiomyopathy. "
01/01/2015 - "Eleven patients on the waiting list for heart transplantation (43.5 ± 7.6 years, 64% male) and eight patients undergoing surgical myectomy for obstructive hypertrophic cardiomyopathy (57.1 ± 8.6 years, 63% male) were recruited and underwent CMR prior to cardiac transplantation or myectomy. "
10/01/2015 - "Current clinical applications mainly include patients after transplant, suspected CAD, and hypertrophic cardiomyopathy."
11/01/2014 - "In hypertrophic cardiomyopathy (HCM), heart transplant has been predominantly confined to patients with systolic dysfunction. "
09/01/2010 - "Heart transplant is a treatment option for selected patients with hypertrophic cardiomyopathy (HCM). "
04/01/2010 - "This is the first case of hypertrophic obstructive cardiomyopathy with predominant RVOT obstruction treated by myectomy and patch graft interpositioning."
12/01/2009 - "Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant."